ECJ backs Ineos over Alpharen brand
Says there will be no confusion with Teva’s Alpha brand
The European Court of Justice has overturned a ban on the UK’s Ineos Healthcare using its trademark Alpharen to sell certain medicines in Hungary, Latvia and Lithuania.
This dispute centres on Ineos medicines containing magnesium iron hydroxy carbonate or hydrotalcite or derivatives used in renal dialysis and treating renal diseases and kidney ailments; and phosphate binders for treating hyperphosphataemia.
Israel’s Teva Pharmaceutical Industries had originally persuaded European Union trademark regulator OHIM that there would be confusion with its ‘Alpha’ brand.
